Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hydrochlorothiazide 25 mg Clear all
Completed Not applicable Interventional

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764
View directory record Official record
Conditions
Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions
Lisinopril, Hydrochlorothiazide
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Salt Loading and Thiazide Intervention Study

NCT00896389
View directory record Official record
Conditions
Hypertension
Interventions
Salt loading, Hydrochlorothiazide (HCTZ)
Procedure · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

NCT01712126
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan and Hydrochlorothiazide, Avalide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 6:53 AM EDT
Completed No phase listed Observational

Genetic Epidemiology of Responses to Antihypertensives

NCT00005520
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Hydrochlorothiazide, Candesartan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

NCT00386607
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo, Hydrochlorothiazide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Anaheim, California • Lomita, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

The SCCS Polypill Pilot Trial

NCT02278471
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

NCT00219102
View directory record Official record
Conditions
Hypertension, Diabetes
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

NCT00654745
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Los Angeles, California • Sylmar, California • Tustin, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

NCT00797316
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

NCT01033071
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
84
States / cities
Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

NCT00649038
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 27, 2026, 6:53 AM EDT
Withdrawn Phase 4 Interventional

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

NCT01822860
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

NCT00698646
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + HCTZ, Valsartan, HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

NCT00170937
View directory record Official record
Conditions
METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

NCT01149473
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

NCT00171405
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

NCT00649597
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 27, 2026, 6:53 AM EDT